Skip to main content

Table 2 Comparison of clinical characteristics at baseline and follow-ups

From: Quantitative assessment of lesion load and efficacy of 3 cycles of albendazole in disseminated cysticercosis: a prospective evaluation

Clinical features

Baseline (N = 29)

1st follow-up (N = 29)

2nd follow-up (N = 29)

3rd follow-up (N = 29)

P value

Seizures (Number of patients)

26 (89.7%)

13 (44.8%)

6 (20.7%)

1 (3.4%)

< 0.001

Seizures (Number of events)

    

< 0.001

• Total

158

64

18

3

 

• Median

4 (2.5–8.0)

0 (0–5.5)

0 (0–0)

0 (0–0)

 

• Maximum

15

9

5

3

 

Headache (Number of patients)

22 (75.9%)

14 (48.3%)

10 (34.5%)

7 (24.1%)

< 0.001

  1. Note: Statistically significant P values have been italicized